Introduction
It is now generally accepted that dopamine released from hypothalamic neurosecretory cells reaches the anterior pituitary gland via the hypophysial portal vessels and exerts a tonic inhibition on prolactin secretion (Macleod, 1976) . Dopamine-receptor blocking drugs will therefore increase the release of prolactin by effectively removing this inhibition (Thorner & Besser, 1978) . In-vitro studies on isolated pituitary tissue have confirmed that dopamine antagonists can block the effects of dopamine on prolactin secretion although at high concentrations these drugs can inhibit the release of prolactin in the absence of dopamine (MacLeod & Lamberts, 1978; Caron et al, 1978) . The mechanism of this paradoxical effect is unknown.
The discovery that the anti-emetic drug, domperidone, is a potent dopamine antagonist which does not readily cross the blood-brain barrier (Laudron & Leysen, 1979) stimulated interest in its effects on prolactin secretion (Cocchi et al, 1980; Kato et al, 1980) . We Text- fig. I . Release of prolactin from perfused male rat pituitary glands and the responses to 5-min 'pulses' of 10 ng TRH/ml when domperidone is included in the perfusing medium at concentrations of (a) 100 pg/ml, (b) 1 pg/ml and (c) 10 ng/ml. Values are mean ± s.e.m. for 6 observations. The asterisks (*) indicate a significant reduction (P < 0-05) in the increment of TRH stimulated prolactin secretion. < 0-05) and the responses to TRH were markedly attenuated (P < 0-05). In-vitro release ofprolactin and LHfrom pituitaries ofdomperidone-pretreated male and female rats Pretreatment of male rats with domperidone had no effect on either the basal or TRH-stimulated release of prolactin from perfused pituitary glands, despite the fact the circulating prolactin levels were raised before death (Text-fig. 3 ). However, in the female rats made hyperprolactinaemic by domperidone treatment, there were marked differences in the Text- fig. 3 . Release of prolactin from perfused pituitary glands of male rats. Treatment with domperidone had no significant effect on the mean basal or TRH-stimulated release of prolactin.
Values are mean ± s.e.m. for 6 observations. release of prolactin from their isolated pituitary glands-the mean basal release of prolactin was significantly higher (P < 0-005) compared with that of the controls (Text-fig. 2a ).
Text- figure 2( The degree of hyperprolactinaemia induced by domperidone treatment was far greater in females than in males, the difference being in the order of 800 ng/ml. Similarly, the release of prolactin from their perfused pituitary glands was significantly higher in the pretreated females compared with the control groups whereas no differences were observed between hyperprolactinaemic and control male rats. Oestrogen increases prolactin secretion (MacLeod, 1976) and probably stimulates prolactin synthesis primarily and its release only secondarily (Nagy, Valdenegro & MacLeod, 1980 (Gudelsky & Porter, 1980) or a direct action of the drug on the dopaminergic control of Gn-RH secretion (Sarkar & Fink, 1981) Since the presence of domperidone in the perfusate also attenuated the LH responses to Gn-RH, a direct effect of the drug cannot be discounted although it is unlikely that such high concentrations of the drug were reaching the pituitary in vivo.
